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Human Respiratory Syncytial Virus (RSV), for which neither a vaccine nor 21 
an effective therapeutic treatment is currently available, is the leading cause of 22 
severe lower respiratory tract infections in children. Interferon stimulated gene 15 23 
(ISG15) is an ubiquitin-like protein that is highly increased during viral infections 24 
and has been reported to play an antiviral or a proviral activity, depending on the 25 
virus. Previous studies from our laboratory demonstrated a strong ISG15 up-26 
regulation during RSV infection in vitro. In this study, an in depth analysis of the 27 
role of ISG15 in RSV infection is presented. ISG15 overexpression and siRNA 28 
silencing experiments, along with ISG15 knockout cells (ISG15-/-) revealed an anti-29 
RSV effect of this molecule. Conjugation inhibition assays demonstrated that 30 
ISG15 exerts its antiviral activity via protein ISGylation. This antiviral activity 31 
requires high levels of ISG15 to be present in the cells before RSV infection. 32 
Finally, ISG15 is also up-regulated in human respiratory pseudo-stratified epithelia 33 
and in nasopharyngeal washes from infants infected with RSV, pointing to a 34 
possible antiviral role of this molecule in vivo. These results advance our 35 
understanding of the innate immune response elicited by RSV and open new 36 
possibilities to control infections by this virus.  37 
 38 
IMPORTANCE 39 
At present no vaccine or effective treatment against human respiratory 40 
syncytial virus (RSV) is available. This study shows that interferon-stimulated gene 41 
15 (ISG15) lowers RSV growth through protein ISGylation. In addition, ISG15 42 
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accumulation highly correlates with RSV load in nasopharyngeal washes from 43 
children, indicating that ISG15 may also have an antiviral role in vivo. These results 44 
improve our understanding of the innate immune response against RSV and 45 
identify ISG15 as a potential target for virus control.  46 




Human Respiratory Syncytial Virus (RSV) is the prototype of the Pneumovirus 49 
genus of the Pneumovirinae subfamily within the Paramyxoviridae family. It is an 50 
enveloped, single-stranded negative sense RNA virus whose genome of 15.2 kb 51 
contains 10 genes encoding a total of 11 proteins (1). These are: Three 52 
glycoproteins (F, G, SH) inserted in the viral envelope; four proteins (N, P, L and 53 
M2-1) associated to the ribonucleoprotein and which are required for RNA 54 
synthesis; an additional protein (M) which forms a protein shell underneath the viral 55 
membrane, and three nonstructural proteins, two of them implicated in modulating 56 
the host innate response to infection (NS1 and NS2) and the other (M2-2) involved 57 
in regulating the switch from RNA transcription to RNA replication (1, 2).  58 
RSV is a leading cause of severe pediatric lower respiratory tract infections but 59 
also a significant cause of morbidity and mortality in the elderly and 60 
immunocompromised individuals (3). Symptoms vary from those of a common cold 61 
to bronchiolitis and pneumonia in serious cases (4). The mortality associated to 62 
acute lower respiratory RSV infections in children under the age of five is estimated 63 
to be 66,000-199,000 deaths per year worldwide (5).  64 
The host response to RSV infection begins in the epithelial cells of the airways, 65 
where virus replication preferentially occurs. Cytokines such as type I interferons 66 
(IFN-α and IFN-β) are one of the first lines of defense against viral infections and 67 
stimulate the expression of a wide range of genes termed interferon-stimulated 68 
genes (ISGs) involved in the antiviral response (6). Many ISGs can also be 69 
induced by dsRNA or viruses in an IFN-independent manner (7, 8).  70 
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RSV has been regarded as a poor IFN inducer as well as a poor responder to 71 
IFN (9-12). In fact, NS1 and NS2 proteins inhibit both IFN production and signaling 72 
(13-19). Infected cells, however, express high levels of ISGs, including ISG15 (20). 73 
ISG15 is an ubiquitin-like protein encoded by the interferon-stimulated gene 15. 74 
Similarly to ubiquitination, ISG15 is conjugated to target proteins through a 75 
conserved C-terminal Gly-Gly motif in a process termed ISGylation (21, 22). This 76 
process is conducted through a sequential reaction catalyzed by E1-activating, E2-77 
conjugating and E3-ligase enzymes which are also induced by type I IFN (23).  78 
UbE1L is the only described E1 enzyme for ISG15 while UbcH8 and HERC5 are 79 
the predominant E2 and E3 enzymes respectively (24-28). ISG15 can be removed 80 
from its target proteins by the ubiquitin-specific protease 18 (USP18), making the 81 
ISGylation process reversible (29, 30). Once ISG15 is conjugated to one of more 82 
than 300 target proteins described (31), it causes either a gain or a loss of function 83 
(23). Interestingly, ISGylation has been described as a co-translational process of 84 
both cellular and pathogen encoded proteins with little specificity (31). In addition to 85 
its conjugated form, free unconjugated ISG15 is present intracellularly and it is also 86 
released to the extracellular space (32, 33). Although the mechanism responsible 87 
for the ISG15 antiviral activity is not fully understood, various studies have reported 88 
an essential role of both conjugated and unconjugated ISG15 in the antiviral 89 
response (34-41). A proviral effect, however, has been described in some cases 90 
(42-44). In contrast, viruses have evolved mechanisms to counteract ISG15 91 
antiviral role; for instance, vaccinia virus E3 protein and influenza B NS1 protein 92 
bind ISG15 antagonizing its activity (24, 45). 93 
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 Despite intensive research, neither a vaccine nor an effective antiviral 94 
therapy against RSV is currently available. A better understanding of the complex 95 
interactions between the virus and the host responses that counteract virus 96 
infection is therefore of great importance (46, 47). While the role of ISG15 in RSV 97 
infection has not been investigated, previous studies from our laboratory 98 
demonstrated a strong induction of this gene as a result of RSV infection in A549 99 
cells (20). In order to determine whether ISG15 may play a role in the innate 100 
immune response elicited by RSV, we characterized ISG15 expression and 101 
ISGylation during RSV infection. Experiments of overexpression of both wild-type 102 
and conjugation-deficient ISG15, silencing of ISG15, UbE1L or USP18 and 103 
infection of ISG15-/- cells demonstrated an antiviral activity of conjugated ISG15 104 
against RSV. In addition, a strong correlation was found between viral infection and 105 
expression of ISG15 in relevant models of infection both in vitro and in vivo.  106 
  107 
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MATERIAL AND METHODS 108 
Cells and virus. 109 
Human lung carcinoma cells (A549) and human carcinoma HeLa derived 110 
cells (HEp-2) were maintained in Dulbecco´s modified Eagle´s medium (DMEM, 111 
Lonza) supplemented with 10% fetal bovine serum (FBS, Biowest), 4 mM L-112 
Glutamine (Lonza), 100 U/ml penicillin (Lonza) and 100 U/ml streptomycin (Lonza). 113 
All cells were incubated at 37ºC in a 5% CO2 atmosphere. To generate viral stocks, 114 
the RSV Long strain was propagated in HEp-2 cells and purified from clarified 115 
culture supernatants by polyethylene glycol precipitation and centrifugation in a 116 
discontinuous sucrose gradient as previously described (20, 48).  117 
Viral infections and plaque assays. 118 
A549 subconfluent monolayers were infected with RSV at a multiplicity of 119 
infection (MOI) of 3 plaque-forming units (pfu) per cell (as indicated in the figure 120 
legend, MOI of 30 or 0.3 was also used in some experiments). Cells were 121 
incubated with the viral inoculum in DMEM 2% FBS (DMEM2) for 90 minutes at 122 
37ºC. After this time, the inoculum was removed and fresh DMEM2 was added. 123 
Cell supernatants for viral titration and cell pellets for RNA and protein extraction 124 
were collected at different hours post-infection (hpi). For cell-associated virus, cells 125 
were washed with DMEM2, scrapped off in fresh DMEM2, disaggregated by 126 
thoroughly pippeting and brief sonication in an ultrasonic bath, and virus titrated in 127 
the clarified supernatant.  128 
To determine the viral titer, HEp-2 cell monolayers were incubated with 129 
serial dilutions of the cell supernatants for 90 minutes at 37ºC and then overlaid 130 
with 0.7% agarose in DMEM2. Five days post-infection (dpi), the cell monolayers 131 
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were fixed with 4% formaldehyde in PBS followed by methanol permeabilization. 132 
Cells were incubated with a mixture of monoclonal antibodies against RSV (20) 133 
and plaques were visualized using an anti-mouse IgG horseradish peroxidase 134 
linked whole antibody (Abcam) and 3-amino-9-ethylcarbazole (AEC, Sigma). 135 
Quantitative RT-PCR and western blots. 136 
Total RNA from mock-infected or infected cells was purified with the RNeasy 137 
Mini Kit (Qiagen) and was reverse transcribed with the High-Capacity cDNA 138 
Archive Kit (Applied Biosystems) following the manufacturer´s instructions. Gene 139 
expression was measured by quantitative RT-PCR (qRT-PCR) with a Step One 140 
instrument (Applied Biosystems) and performed in triplicate following the 141 
manufacturer´s protocols. PCR primers and TaqMan MGB probes (FAM dye-142 
labeled) for the following genes were used: β-actin (Hs99999903_m1), ISG15 143 
(Hs00192713_m1), UbE1L (Hs00163295_m1), USP18 (Hs00276441_m1), IFIT1 144 
(Hs00356631_g1), RIG-I (Hs00204833_m1) and RSV nucleoprotein (forward 145 
primer: 5´CATGATTCTCCTGATTGTGGGATGA3´, reverse primer: 146 
5´TCACGGCTGTAAGACCAGATCTAT3´, probe: 5´CCCCTGCTGCCAATTT3´) 147 
(Applied Biosystems). Gene expression was normalized to the β-actin expression 148 
and the comparative CT (ΔΔCT) method was used for relative quantifications.  149 
Protein expression was analyzed by western blot. Cell pellets were 150 
resuspended in sodium-deoxycholate lysis buffer and protein concentration was 151 
determined using a Bradford protein assay (Biorad). A total of 10μg of each protein 152 
sample was separated in 10% or 15% SDS-PAGE gels and subsequently 153 
transferred to an immobilon-P membrane (Milipore). Primary antibodies for 154 
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detection of the following proteins were used: ISG15 (H150sc-50366, Santa Cruz), 155 
β-actin (8224-100, Abcam), RSV phosphoprotein (67P), RSV G glycoprotein 156 
(021/1G), RSV fusion protein (476-510) and RSV nucleoprotein (79N) (49, 50). 157 
Horseradish peroxidase-linked anti-rabbit or anti-mouse Ig (Abcam) were used as 158 
secondary antibodies. Proteins were visualized by chemiluminiscence using Clarity 159 
Western ECL Substrate (Biorad) in a Gel Logic 1500 Imaging System instrument 160 
(Kodak). The intensity of the protein bands was quantified by using Image J 161 
software (http://rsb.info.nih.gov/ij/index.html) and standardized against β-actin. 162 
ISG15 overexpression assays. 163 
Total RNA from A549 RSV-infected cells was reverse transcribed with the 164 
High-Capacity cDNA Archive Kit using an oligo-dT primer (Applied Biosystems) 165 
and ISG15 was amplified using the following primers: forward 166 
(5´AAAAGCGGCCGCGGTGCTGCCTGCCGAAG3´) and reverse 167 
(5´AAAAGCGGCCGCTCTTTACAACAGCCTTTATTTCCG3´). The PCR product 168 
was cloned into the mammalian vector pCMV6-Neo (Origene) and the resulting 169 
plasmid pCMV6-Neo-ISG15 was sequenced in order to verify that the ISG15 170 
sequence was correct. Synthesis of the non-conjugative ISG15 plasmid pCMV6-171 
Neo-ISG15-LRAA from pCMV6-Neo-ISG15 was performed by directed 172 
mutagenesis using the Phusion Site-directed Mutagenesis kit (Thermo Scientific) 173 
following the manufacturer´s instructions with the following primers: forward 174 
(5´CCTGCGGGCAGCCGGCACAGAGCCTGGCGGGCGGAGC3´) and reverse 175 
(5´GGCTGCCCGCAGGCGCAGATTCATGAACACGGT3´).  176 
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For overexpression assays, 5 x 104 A549 cells were plated in each well of a 177 
12-well plate and incubated for 60 hours before transfection. Cells were then 178 
transfected with 1 μg of purified plasmid (EndoFree Plasmid Maxi Kit, Qiagen) and 179 
4μl of Lipofectamine 2000 (Invitrogen) per well. Twenty-four hours after 180 
transfection, the cells were infected with RSV at a MOI of 3. Cell supernatants for 181 
viral titration and cell pellets for RNA and protein extraction were collected at 182 
different hpi. 183 
siRNA silencing. 184 
A549 cells were plated 24 hours before transfection at a density of 5 x 104 185 
cells per well in 24-well plates. Cells were transfected with 6 pmol of control small 186 
interfering RNAs (siRNAs) or specific siRNAs against ISG15, UbE1L or USP18 187 
(Ambion) and 1 μl of Lipofectamine RNAiMAx reagent (Invitrogen) per well. 188 
Twenty-four hours after transfection, cells were infected with RSV at a MOI of 3. In 189 
the case of IFN-β treatment, culture medium was replaced four hours after 190 
transfection with fresh medium containing 500 U/ml of IFN-β (pbl assay science) 191 
and maintained during the whole infection period. Cell supernatants for viral 192 
titration and cell pellets for RNA and protein extraction were harvested at different 193 
hpi, as indicated in the figure legends. 194 
ISG15 knockout A549 cells. 195 
Two clones of ISG15 knockout (ISG15-/-) A549 cells were generated using 196 
the Transcription Activator-Like Effector Nucleases (TALENs) technology. This 197 
technology allows generating knockout cells by using sequence-specific DNA-198 
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cleaving enzymes against specific target genes (51). Cells were transfected as 199 
described above with the purified plasmids Human-H36698_TALEN_L1 and 200 
Human-H36698_TALEN_R1 (Talen Library Resource, Seoul National University). 201 
Three days after transfection, cells were trypsinized and cloned by limiting dilution 202 
in 96-well plates at a density of one cell per well. Single cell clones were selected 203 
and expanded to generate stocks. Cell DNA was extracted with the Cyclo-Prep 204 
Genomic DNA Purification kit (Amresco) following the manufacturer´s instructions. 205 
Screening for ISG15-/- clones was conducted by PCR amplification and DNA 206 
sequencing using the following primers: forward 207 
(5´GAGCAGCTCCATGTCGGTGTC3´) and reverse 208 
(5´ACACGGTGCTCAGGGGCTTG3´). ISG15-/- clones were confirmed by western 209 
blot using an ISG15 specific antibody. All selected clones were grown, cloned a 210 
second time by limiting dilution, and checked again by sequencing and western 211 
blot to ensure that they did not express ISG15. Two wild-type clones that 212 
underwent the same process of transfection and cloning were selected as controls. 213 
Virus growth was monitored in wild-type and ISG15-/- cells treated or not with 214 
500 U/ml of IFN-β 20 hours before infection. Cell supernatants were collected for 215 
virus titration at 48 hpi. 216 
Pseudo-stratified epithelia.  217 
Human lung tissue samples were obtained from patients who underwent 218 
surgery for lung carcinoma. Experiments were approved by the local ethics 219 
committee and informed consent was obtained. Human bronchial epithelial cells 220 
were obtained from normal tissue and differentiated to multilayered epithelia as 221 
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previously described (52). Samples were mock-infected or infected with RSV at 222 
7x106 pfu/cm2 and cells were collected at different dpi, RNA was extracted with 223 
TRIZOL reagent (Invitrogen) and further purified and reverse-transcribed as 224 
described above. Samples were analyzed by qRT-PCR using specific RSV 225 
nucleoprotein and ISG15 probes.  226 
Nasopharyngeal wash samples. 227 
Nasopharyngeal wash samples from 19 children up to 24 months old 228 
infected with RSV were harvested at admission and discharge by instillation of 2.5 229 
ml of a an isotonic saline solution into each nostril (NaCl 0.9%) as described 230 
elsewhere (53). In all cases, an informed consent was requested from the parents 231 
or legal guardians prior to the inclusion of the child in the study. Approval of the 232 
Committee for Ethics in Clinical Research of the “Hospital Clínico Universitario” in 233 
Valladolid (Spain) was obtained prior to the beginning of recruitment. Total RNA 234 
was extracted, reverse transcribed and gene expression quantified as described 235 
above.  236 




RSV infection induces ISG15 expression and protein ISGylation.  239 
To investigate if ISG15 expression is up-regulated after in vitro RSV 240 
infection, A549 cells were infected and the levels of ISG15 and RSV nucleoprotein 241 
RNAs were analyzed by qRT-PCR at different hpi. Fig. 1A shows a large increase 242 
of ISG15 RNA in RSV infected A549 cells in a time-dependent manner. The 243 
increase started between 6 to 16 hpi, reaching maximum level 48 hpi. ISG15 RNA 244 
increase showed a delay of 4-5 hours with respect to RSV nucleoprotein RNA (Fig. 245 
1A). A high correlation between ISG15 and nucleoprotein RNA expression was 246 
observed (R2=0.97, P<0.0001) (Fig. 1B). 247 
To confirm the above results and to determine whether the RNA levels of 248 
ISG15 and RSV nucleoprotein were translated to the protein levels, samples from 249 
a parallel infection were analyzed by western blot at various hpi. RSV 250 
nucleoprotein started to be detected 4 hpi (Fig. 1C) and increased continuously 251 
until 48 hpi. RSV infected A549 cells expressed large amounts of both free ISG15 252 
and ISG15 conjugates. Accumulation of free ISG15 was time-dependent, 253 
becoming apparent 16 hpi, while the increase of ISG15 conjugates was not evident 254 
until 30-36 hpi. As described for RNAs, ISG15 protein increase had a delay of 4-5 255 
hours with respect to the RSV nucleoprotein accumulation (Fig. 1C). 256 
Finally, the protein ISGylation patterns obtained after 48 hours of RSV 257 
infection or IFN-β stimulation were compared by western blot. The results obtained 258 
revealed common bands being labelled but, additionally, some specific bands 259 
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appearing only in RSV infected cells or IFN-β stimulated cells were apparent (Fig. 260 
1D); i.e.,  RSV induced ISGylation differs to some extent from that of IFN-β. 261 
RSV titer as well as viral proteins and RNA levels are increased in ISG15 262 
knockdown or ISG15-/- cells stimulated with IFN-β. 263 
To analyze whether or not ISG15 has any anti-RSV activity, A549 cells were 264 
transfected with control siRNAs or specific ISG15 siRNAs before being infected 265 
with RSV. No differences were observed in viral titer between ISG15-silenced cells 266 
and control cells (Fig. 2A, -IFN-β). It was hypothesized that this lack of antiviral 267 
effect could be related to the fact that ISG15 expression and formation of ISG15 268 
conjugates is delayed with respect to virus replication (Fig. 1A and 1C). Hence, 269 
ISG15 expression was induced before RSV infection by stimulation of cells with 270 
IFN-β. As expected, a decrease in viral titer was observed in IFN-β treated cells 271 
when compared with non-treated controls (Fig. 2A). However, an increase of 2.9 272 
times in virus titer was observed in the ISG15-silenced cells with respect to control 273 
cells, indicative of an ISG15 assisted anti-RSV effect (Fig. 2A, +IFN-β ). 274 
In addition to virus titers, the amount of accumulated viral nucleoprotein and 275 
RNA was quantified at 24 and 48 hpi in control and ISG15-silenced cells previously 276 
stimulated with IFN-β. As expected, a clear inhibition of free ISG15 and ISG15 277 
conjugates was observed in ISG15-silenced cells by western blot (Fig. 2B). At the 278 
same time, ISG15-silenced cells showed an increase in the amount of the RSV 279 
nucleoprotein at 24 and 48 hpi compared with control cells (Fig. 2B). Furthermore, 280 
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a significant increase on the amount of RSV nucleoprotein RNA was observed in 281 
ISG15-silenced cells when compared with control cells at the same hpi (Fig. 2C).  282 
To confirm the above results, ISG15-/- cells were generated using TALEN 283 
nucleases. Two wild-type and two ISG15-/- cell clones were selected for further 284 
studies (Fig. 3A). These four clones, along with the uncloned wild-type cells, were 285 
infected either in the absence or presence of IFN-β at a MOI of 3 and viral titers 286 
were determined 48 hours later. As expected, no significant differences were found 287 
among the untreated wild-type or ISG15-/- cells. However, in the IFN-β treated 288 
cells, a significant increase (from 1.9 to 4.6-fold) in viral titer was found in ISG15-/- 289 
cells, compared with wild-type cells (Fig. 3B). Together, these results demonstrate 290 
that ISG15 has an anti-RSV activity in cells previously stimulated with IFN-β. 291 
When RSV infections were carried out at MOI 30 or 0.3, an increase in virus 292 
titer was also observed in ISG15-/- cells previously treated with IFN-β (Fig. 3C). The 293 
magnitude of this effect seemed to decrease as MOI increased, suggesting that 294 
ISG15 inhibition was more effective with lower input virus, as otherwise might be 295 
expected for a partial block in virus replication. 296 
ISG15 overexpression before virus infection reduces RSV titer as well as 297 
viral proteins and RNA accumulation.  298 
The results from previous sections indicated that the high levels of ISG15 299 
induced by RSV infection had no antiviral effect. However, this antiviral effect was 300 
revealed when ISG15 was overexpressed before virus infection by stimulation of 301 
cells with IFN-β. ISG15 might need the collaboration of other proteins induced by 302 
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IFN-β for its antiviral activity or it may be just a matter of the time period at which 303 
IS15 is expressed in relation to virus infection. To distinguish between these two 304 
possibilities, A549 cells were either transfected with a plasmid overexpressing 305 
ISG15 or with the same empty vector as a negative control, and then infected with 306 
the RSV. Cell supernatants were harvested at 24 and 48 hpi and viral titers 307 
determined by plaque assay. A significant reduction of the viral titer (4.8-fold) was 308 
observed in the ISG15 overexpressing cells when compared with control 309 
transfected cells at 48 hpi (Fig. 4A). Western blot analysis of four viral proteins 310 
revealed decreased accumulation in the ISG15 transfected cells compared with 311 
control cells. This decrease was observed at 24 and 48 hpi, with the most evident 312 
effect at 24 hours (Fig. 4B). In addition, the RSV nucleoprotein RNA was analyzed 313 
by qRT-PCR at the same hpi. The results showed a significant RNA reduction in 314 
the ISG15 overexpressing cells compared to control cells at both 24 and 48 hpi 315 
(Fig. 4C).  316 
Therefore, these findings support the conclusions reached with ISG15-317 
silenced or ISG15-/- cells and demonstrated that ISG15 has an anti-RSV activity 318 
when overexpressed before virus infection, either alone or in the context of the 319 
antiviral response induced by IFN-β. 320 
Antiviral activity of ISG15 against RSV is due to protein ISGylation. 321 
In order to determine if ISG15 accomplishes its antiviral activity against RSV 322 
in a conjugated or unconjugated form, experiments were carried out using three 323 
different approaches:  324 
17 
 
First, since a C-terminal Gly-Gly motif is required for ISG15 conjugation (21, 325 
22), a plasmid was generated by site-directed mutagenesis in which those two 326 
residues were mutated to Ala. This plasmid therefore expresses an ISG15 protein 327 
that cannot be conjugated to target proteins. A549 cells were transfected with the 328 
plasmid expressing either wild-type ISG15, the plasmid expressing non-conjugative 329 
ISG15 or an empty vector. Twenty-four hours later, cells were infected with RSV 330 
and virus titers were measured at 48 hpi. As expected, a significant decrease (3.9-331 
fold) was found in the viral titer of cells overexpressing wild-type ISG15 when 332 
compared with control cells transfected with the empty vector. However, no 333 
differences were found between these control cells and cells transfected with the 334 
non-conjugative ISG15 plasmid (Fig. 5A). Similar results were obtained after 335 
transfection/infection experiments of ISG15-/- cells, demonstrating that their 336 
phenotype can be reconstituted by wild-type ISG15 but not by non-conjugative 337 
ISG15 (Fig. 5B). 338 
A second approach to inhibit the formation of ISG15 conjugates was 339 
knocking down the only identified E1 enzyme for ISG15, UbE1L (24). A549 cells 340 
were either transfected with control siRNAs or specific UbE1L siRNAs and then 341 
infected with RSV in either the absence or presence of IFN-β. IFN-β-stimulated 342 
UbE1L-silenced cells expressed high levels of free ISG15, as did control cells, but 343 
failed to form ISG15 conjugates (Fig. 5C). Besides, similarly to what happened with 344 
ISG15-silenced cells, UbE1L inhibition led to an important increase in the amount 345 
of RSV nucleoprotein at 24 and 48 hpi (Fig. 5C). Also, resembling the results of 346 
infecting ISG15-silenced cells with RSV (Fig. 2A), no differences were found 347 
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between the UbE1L-silenced cells and control cells in the absence of IFN-β 348 
stimulation (Fig. 5D, -IFN-β). In contrast, a significant increase (3.9-fold) in viral 349 
titer was observed in the UbE1L-silenced cells and treated with IFN-β when 350 
compared with control cells (Fig. 5D, +IFN-β). 351 
 The third approach consisted in silencing of USP18, an ISG15-specific 352 
deconjugating protease that removes ISG15 from its protein targets (29, 30). As 353 
expected, the results were the opposite of those obtained from UbE1L silencing 354 
experiments: in IFN-β treated cells, USP18 silencing increased protein ISGylation, 355 
decreased RSV nucleoprotein accumulation (Fig. 5E) and reduced virus titers (3.3-356 
fold) (Fig. 5F).    357 
Altogether, these data indicate that ISGylation, rather than free ISG15, is 358 
responsible for the anti-RSV activity of this molecule. 359 
In addition to its role in protein ISGylation, it has been reported that ISG15 360 
and USP18 act together to counteract IFN-α/β signaling (54, 55). Hence, the 361 
expression of IFIT1 and RIG-I (two ISGs) was measured in cells silenced for 362 
ISG15, UbE1L or USP18 that were previously treated with IFN-β and then infected 363 
with RSV. As expected, a slight increase in the expression of IFIT1 and RIG-I 364 
mRNA was observed in cells knocked down for ISG15 or USP18, but not for 365 
UbE1L (Fig. 6). Despite having similar effect on IFIT1 and RIG-I expression, ISG15 366 
and USP18 silencing had opposite effect on RSV growth (Fig. 2A and 5F), 367 
indicating that, with regard to RSV inhibition, the effect on protein ISGylation 368 
predominates over the effect on ISGs expression. It cannot be excluded, however, 369 
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that the overexpression of ISGs may contribute somewhat to reduce RSV titer in 370 
USP18 knocked down cells.     371 
The ISG15 anti-RSV activity affects a post-entry stage of infection before 372 
virus release.  373 
Since it has been shown that ISG15 may affect virus entry (56) or release 374 
(34, 37), two experiments were carried out to gain information about the role of 375 
ISG15 in those steps of RSV replication.   376 
First, A549 cells were transfected with a plasmid expressing ISG15 or a 377 
control plasmid before being infected with RSV under single infectious cycle 378 
conditions. Then, the accumulation of RSV nucleoprotein RNA was quantified by 379 
qRT-PCR at several hpi. The results showed a significant RNA reduction in the 380 
ISG15 overexpressing cells compared to control cells starting between 8-15 hpi 381 
(Fig. 7A). This result shows that ISG15 restricts RSV growth at a post-entry stage 382 
of infection. 383 
 In addition, the virus released to the supernatant and the virus associated to 384 
cells was quantified in ISG15- or control-transfected cells. As expected from 385 
previous experiments a more than three-time reduction in virus titer was observed 386 
in the supernatant of ISG15-transfected cells with respect to control-transfected 387 
cells (Fig. 7B, supernatant). Similarly, a significant decrease of more than two-fold 388 
was also observed in virus titers from the cell-associated fraction of ISG15-389 
transfected cells when compared to the same fraction of control cells (Fig. 7B, cell-390 
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associated). This indicates that an ISG15-mediated restriction on RSV infection 391 
occurs before virus release.       392 
ISG15 expression correlates with RSV infection in pseudo-stratified 393 
respiratory epithelia and in nasopharyngeal washes from infants. 394 
As a preliminary step to investigate the role of ISG15 in the anti-RSV 395 
response in vivo, its expression was analyzed in more relevant models of infection. 396 
Firstly, an in vitro model of differentiated pseudo-stratified columnar respiratory 397 
epithelium with ciliated and mucus producing cells that resembles in vivo 398 
conditions was used for RSV infection (52). Differentiated cultures from six donors 399 
were infected and viral yield and ISG15 expression were quantified by qRT-PCR at 400 
different dpi. ISG15 levels of infected samples correlated with RSV nucleoprotein 401 
expression in every sample and time post-infection tested. A high positive 402 
correlation (R2=0.77, P<0.0001) between viral infection and the ISG15 expression 403 
level was observed (Fig. 8A).  404 
Secondly, nasopharyngeal washes from 19 young infants infected with RSV 405 
were obtained at admission and discharge (38 samples in total). After RNA 406 
extraction, RSV nucleoprotein and ISG15 RNA levels were determined by qRT-407 
PCR. Similarly to the pseudo-stratified epithelia, a high positive correlation 408 
(R2=0.63, P=0.0004) between RSV nucleoprotein and ISG15 expression was 409 
observed (Fig. 8B). These data demonstrate that ISG15 is induced by RSV 410 
infection in vivo and suggest that ISG15 may play an antiviral role after natural 411 




In this study, the antiviral activity of ISG15 against RSV was investigated. 414 
RSV infection of A549 cells induced high levels of both free and conjugated ISG15. 415 
Furthermore, overexpression of ISG15, or pretreatment with IFN-β of cells that 416 
were ISG15-silenced or ISG15-/-, demonstrated that ISG15 played an important 417 
role as an anti-RSV molecule. The ISG15 antiviral activity required protein 418 
ISGylation as was evidenced by the lack of effect of a non-conjugative form of 419 
ISG15, the inhibition of ISGylation by UbE1L silencing or the increase of ISGylation 420 
by USP18 knockdown. Moreover, a high correlation between RSV infection and 421 
ISG15 expression was established both in a relevant model of infection, such as 422 
human respiratory pseudo-stratified epithelia, and in nasopharyngeal washes from 423 
infected children. 424 
Although the antiviral activity of ISG15 has been widely described (57, 58), 425 
the mechanisms through which ISG15 exerts its effects have only been hinted in 426 
some cases. The antiviral activity of ISG15 has been described to occur in the late 427 
stages of the viral cycle of HIV and in Ebola virus infections, where ISG15 inhibits 428 
virus release (34, 37). In contrast, it has been recently described that ISG15 429 
inhibits early steps, such as entry and/or uncoating, of the Murine norovirus life 430 
cycle,  although no specific target proteins responsible for these effects have been 431 
identified (56). ISG15 has been claimed to exert its antiviral activity by conjugation 432 
to either viral or cellular proteins. For instance, ISGylation of the NS1 protein of 433 
Influenza A virus reduced its capacity to antagonize the host antiviral response (59, 434 
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60) and ISG15 conjugation to IRF3 during Sendai virus infection inhibited its 435 
proteasome-mediated degradation, boosting the host antiviral response (61). 436 
Our results show that, in order to exert its anti-RSV activity, ISG15 has to 437 
accumulate to high amounts before virus infection. They also indicate that ISG15 438 
carry out its anti-RSV action after virus entry. In addition, ISG15 seems to affect a 439 
stage in the RSV cycle before virus release, since RSV titers decreased in both 440 
released and cell-associated virus following ISG15 overexpression. Given that 441 
ISGylation is ordinarily a co-translational modification (31), it is possible that the 442 
ISG15 anti-RSV activity is mediated by direct ISGylation of viral and/or cellular 443 
proteins essential for virus replication. In this situation, in the first RSV infected 444 
cells, ISG15 would not have an antiviral effect because most viral proteins have 445 
already accumulated to high levels before the ISGylation machinery is triggered. In 446 
cells that acquire an antiviral state before virus infection, such as those stimulated 447 
by interferon, the ISGylation machinery is ready to operate as soon as the virus 448 
enters into the cell. In this case, ISG15 may interfere with RSV replication by 449 
ISGylation of viral or cellular proteins required for RNA replication/transcription, 450 
being P, L, M2-1 and M2-2 obvious protein viral targets which are now under study. 451 
Additionally, or alternatively, binding of certain RSV protein(s) to ISG15 may be 452 
required to antagonize its antiviral effect, as occurs with vaccinia virus E3 or 453 
influenza B NS1 proteins (24, 45). In this case, when ISG15 levels increase in the 454 
first RSV infected cells, the amount of viral proteins has already reached levels 455 
capable of neutralizing ISG15 activity. In contrast, when ISG15 is expressed at 456 
high levels before virus infection, as in cells previously stimulated by IFN-β, no viral 457 
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proteins are present to counteract the ISG15 antiviral effect. The same reasoning 458 
would apply if RSV protein(s) antagonize any of the enzymes involved in 459 
ISGylation, instead of ISG15 directly. 460 
It has been shown that USP18 regulates negatively the IFN-α/β signaling 461 
independently of its ISG15 isopeptidase activity (54) (Fig. 9).This regulation 462 
required ISG15 to stabilize USP18, a process that was ISGylation-independent 463 
since it was mediated by non-conjugating ISG15 and it was not affected by UbE1L 464 
silencing (55). According to this, the lack of ISG15 would destabilize USP18 465 
leading to an increased response to IFN type I and viral resistance (55) (Fig. 9). In 466 
line with this, we have observed a modest increase in the expression of the 467 
interferon stimulated genes IFIT1 and RIG-I in both ISG15 and USP18 silenced 468 
cells treated with IFN-β and infected with RSV (Fig. 6). By contrast, UbE1L 469 
silencing reduced the expression of those genes (Fig. 6), perhaps by increasing 470 
free ISG15 levels due to impaired ISGylation. Our results, however, demonstrated 471 
that the anti-RSV activity of ISG15 in A549 cells was ISGylation-dependent and 472 
largely independent of its effect on USP18 stabilization because: i) non-conjugating 473 
ISG15 is able to stabilize USP18 (55), but it does not have any effect on RSV 474 
replication (Fig. 5A and 5B); ii) UbE1L silencing had no effect on USP18 475 
stabilization (55), but it increased virus titers in IFN-β treated cells (Fig 5D); iii) 476 
while ISG15 and UbE1L silencing had opposite effects on the expression of IFIT1 477 
and RIG-I (Fig. 6), both increased RSV replication (Fig. 2A and 5D); and iv) ISG15 478 
or USP18 silencing in IFN-β treated cells had opposite effects on RSV titers (Fig. 479 
2A and 5F), consistent with the ISG15 isopeptidase activity of USP18 but contrary 480 
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to the results expected from a joint action of ISG15 and USP18, such as that 481 
observed in the IFN response regulation (Fig. 9). Our results agree with the 482 
recently reported observations showing that selective inactivation of the USP18 483 
isopeptidase activity in knock-in mice enhanced protein ISGylation and resistance 484 
against vaccinia and influenza B viruses without inducing any obvious changes in 485 
the IFN signaling pathway (62).  486 
The positive correlation observed in this study between RSV infection and 487 
ISG15 expression in human pseudo-stratified epithelia and in nasopharyngeal 488 
washes from infected children point to a role in RSV infections in vivo. Virus 489 
replication in infected cells generates products that act as pathogen associated 490 
molecular patterns (PAMPs), which directly trigger intracellular innate pathways 491 
leading to the expression of ISG15 and other antiviral and proinflammatory genes 492 
that initiate the immune response (7, 8). In this setting, uninfected respiratory 493 
epithelial cells might acquire an antiviral status,  which includes high levels of 494 
ISG15, through stimulation by IFN secreted from neighboring infected cells and/or 495 
immune cells attracted to the site of infection in the respiratory tract (63, 64). 496 
Subsequent infection of those cells by RSV would be impaired by the previously 497 
acquired antiviral state. In this scenario, ISG15 would play an important role to 498 
hinder RSV dissemination. In addition, overexpression of ISG15 during RSV 499 
infection may contribute to control the excessive inflammation by stabilizing USP18 500 
(55). The role of ISG15 in viral infections in vivo requires, however, further 501 
investigation since it seems to be complex and multifaceted, as demonstrated by 502 
conflicting results from ISG15-deficient human and mice (55, 57), as well as by the 503 
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identification of a novel ISG15 conjugation-dependent mechanism by which mice 504 
are protected against influenza A and Sendai virus infection without obvious effect 505 
on virus replication and immune response (65), which contrast with the observation 506 
that protein ISGylation restricted virus replication and enhanced resistance to 507 
vaccinia virus and influenza B virus in mice (62).     508 
The close correlation between RSV load and ISG15 expression in infants 509 
and the fact that ISG15 is secreted to human fluids, where it can be quantified, 510 
raises the possibility to use this molecule to monitor RSV-induced inflammation 511 
(66). Related to this, it is important to stress that ISG15 levels decreased between 512 
admission and discharge, for every single infant, reflecting the reduction in virus 513 
load and inflammation (data not shown).  514 
In conclusion, we have described for the first time that ISG15 has a 515 
conjugation-dependent antiviral activity against RSV. In addition, data from 516 
nasopharyngeal washes from infants infected with RSV suggest that ISG15 may 517 
play an important role in RSV infection in vivo. Therefore, although further research 518 
is required to elucidate the mechanisms of ISG15 interference with RSV, this study 519 
enhances our understanding of the innate immune response against RSV and 520 
identifies ISG15 as a potential target for virus control.   521 
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 FIGURE LEGENDS 712 
Figure 1. RSV infection of A549 cells enhances ISG15 expression and protein 713 
ISGylation. (A) A549 cells were infected with RSV at a MOI of 3 and harvested at 714 
the indicated hpi. RSV nucleoprotein and ISG15 RNAs were quantified by qRT- 715 
PCR. Data represent the fold increase of ISG15 RNA in infected cells compared 716 
with mock infected cells, and the fold increase of RSV nucleoprotein RNA with 717 
respect to zero hpi. (B) Linear regression plot of RSV nucleoprotein and ISG15 718 
RNA expression data from graphic A. (C) A549 cells were infected with RSV and 719 
harvested at the indicated hpi. Protein accumulation was analyzed by western blot 720 
using anti ISG15 and anti RSV nucleoprotein specific antibodies. Normalization 721 
was carried out using an anti β-actin antibody. (D) Western blot comparing protein 722 
ISGylation patterns induced by interferon-β (500 U/ml) or RSV infection after 48 723 
hours. Arrows show treatment-specific ISGylated proteins. 724 
Figure 2. ISG15 downregulation in IFN-β stimulated cells increases viral titer 725 
and viral protein and RNA levels. (A) A549 cells were transfected with either 726 
control siRNAs or ISG15 siRNAs and infected twenty four hours later at a MOI of 3. 727 
In the case of IFN-β treatment, culture medium was replaced four hours after 728 
transfection with fresh medium containing 500 U/ml of IFN-β and maintained during 729 
the whole infection period. Cell supernatants were harvested at 48 hpi and virus 730 
titer was determined by plaque assays. (B) Protein extracts from IFN-β-treated 731 
RSV-infected cells were collected 24 or 48 hpi and analyzed by western blot using 732 
anti ISG15 and anti RSV nucleoprotein specific antibodies. Proteins were 733 
35 
 
quantified and normalization was carried out using an anti β-actin antibody. (C) 734 
IFN-β treated cells were either transfected with control siRNAs or ISG15 siRNAs 735 
and then infected with RSV. RSV nucleoprotein RNA was quantified by qRT-PCR 736 
at the indicated hpi in ISG15 silenced cells and represented as a percentage of the 737 
nucleoprotein RNA expressed in cells transfected with a control siRNA (100%). 738 
Data from (A) and (C) represent the mean and standard deviation from at least 739 
three independent experiments. Comparisons between conditions were done using 740 
the t test. * P< 0.05; ** P< 0.01. 741 
Figure 3. ISG15 knockout in IFN-β stimulated cells leads to an increase in 742 
viral titer. (A) Two ISG15-knockout A549 cell lines (ISG15-/-) (lanes 4 and 5) were 743 
generated by using TALENs nucleases, and ISG15 expression was checked by 744 
western blot using specific antibodies. Uncloned wild type cells (lane 1) and two 745 
wild type cell clones (lanes 2 and 3) were included as controls. (B) ISG15 wild type 746 
cells and ISG15-/- cells were either left untreated or treated with IFN-β prior to RSV 747 
infection at MOI of 3. (C) Similar experiments were carried out at MOI of 0.3 and 30 748 
in clones #3 (WT) and #5 (ISG15-/-).  Cell supernatants were harvested 48 hpi (MOI 749 
of 3 and 30) or 72 hpi (MOI of 0.3) and virus titers determined by plaque assays. 750 
Data represent the mean and standard deviation from three independent 751 
experiments. Comparisons between groups were done by the t test. ** P< 0.01. 752 
Lanes: 1, uncloned wild type cells; 2 and 3, wild type cell clones; 4 and 5, ISG15-/- 753 
cell clones. 754 
Figure 4. ISG15 overexpression leads to a decrease in viral titer, proteins and 755 
RNA. A549 cells were either transfected with an ISG15 overexpressing plasmid or 756 
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a control plasmid and infected at a MOI of 3 with the RSV 24 hours later. (A) Cell 757 
supernatants were collected and virus titer determined by plaque assay at 48 hpi. 758 
(B) Protein extracts from a representative experiment were collected at 24 and 48 759 
hpi and analyzed by western blot using antibodies against ISG15, and the following 760 
RSV proteins: glycoprotein (G), phosphoprotein (P), fusion protein (F) and 761 
nucleoprotein (N). Proteins were quantified and normalization was carried out 762 
using an anti β-actin antibody. 1, Cells transfected with a control plasmid and 2, 763 
cells transfected with the ISG15 plasmid. (C) RSV nucleoprotein RNA was 764 
quantified by qRT-PCR at 24 and 48 hpi. Data represent the percentage of 765 
expression of RSV nucleoprotein RNA in ISG15-transfected cells compared with 766 
cells transfected with a control plasmid (100%). Data from (A) and (C) represent 767 
the mean and standard deviation from four independent experiments. Comparisons 768 
between groups were done by the t test. * P< 0.05; ** P< 0.01.    769 
Figure 5. Antiviral activity of ISG15 against RSV is due to protein ISGylation. 770 
(A) A549 cells were transfected with either a control plasmid, a plasmid 771 
overexpressing ISG15 or a plasmid overexpressing non-conjugative ISG15 772 
(ISG15-LRAA), and infected 24 hours later with RSV at a MOI of 3. Cell 773 
supernatants were collected at 48 hpi and viral titers determined by plaque assay. 774 
(B)  ISG15-/- A549 cells were transfected, infected and virus titer determined as in 775 
panel A. (C) IFN-β treated A549 cells were transfected with either control siRNA or 776 
UbE1L siRNAs and infected 24 hours later with RSV at a MOI of 3. Protein extracts 777 
were collected at 24 and 48 hpi and analyzed by western blot using anti ISG15 and 778 
anti RSV nucleoprotein specific antibodies. Proteins were quantified and 779 
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normalization was done using an anti β-actin antibody. (D) Untreated and IFN-β 780 
treated A549 cells were either transfected with control siRNAs or UbE1L siRNAs 781 
prior to RSV infection. Cell supernatants were collected 48 hpi and virus titers 782 
determined by plaque assays. (E) and (F) A549 cells were treated as in panels C 783 
and D but USP18 siRNA, rather than UbE1L siRNA, was used for gene silencing. 784 
In the case of IFN-β treatment (C, D, E and F), culture medium was replaced four 785 
hours after transfection with fresh medium containing 500 U/ml of IFN-β and 786 
maintained during the whole infection period. Data represent the mean and 787 
standard deviation from at least three independent experiments. Comparisons 788 
between groups were done by the t test. * P< 0.05. 789 
Figure 6. ISGs expression in ISG15, UbE1L and USP18 silenced cells. IFN-β 790 
treated cells were either transfected with control siRNAs or ISG15 (A), UbE1L (B) 791 
or USP18 siRNAs (C) and then infected with RSV. IFIT1 and RIG-I mRNA was 792 
quantified by qRT-PCR at the indicated hpi in silenced cells and represented as a 793 
percentage of the mRNA expressed in cells transfected with a control siRNA 794 
(100%). Data from (A), (B) and (C) represent the mean and standard deviation 795 
from three independent experiments. Comparisons between conditions were done 796 
using the t test. * P< 0.05. 797 
Figure 7. The anti-RSV activity of ISG15 affects a post-entry stage of infection 798 
before virus release. A549 cells were either transfected with an ISG15 799 
overexpressing plasmid or a control plasmid and infected at a MOI of 3 with the 800 
RSV 24 hours later. (A) RSV nucleoprotein RNA was quantified by qRT-PCR at 801 
different hpi. Data represent the percentage of expression of RSV nucleoprotein 802 
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RNA in ISG15-transfected cells compared with cells transfected with a control 803 
plasmid (100%). (B) RSV titer in the culture supernatant or associated with cells 804 
was determined by plaque assay at 48 hpi. For cell-associated virus, cells were 805 
washed with DMEM2, scrapped off in fresh DMEM2, disaggregated by thoroughly 806 
pipetting and brief sonication in an ultrasonic bath, and virus titrated in the clarified 807 
supernatant.  Data from (A) and (B) represent the mean and standard deviation 808 
from three independent experiments. Comparisons between groups were done by 809 
the t test. * P< 0.05; ** P< 0.01.  810 
Figure 8. ISG15 expression correlates with RSV infection in vitro and in vivo. 811 
(A) Pseudo-stratified epithelia were generated in vitro from lung explant of six 812 
donors and either mock-infected or infected with RSV for two and four days (five 813 
individuals) or three days (one individual). RNA was extracted and ISG15 and RSV 814 
nucleoprotein RNA was quantified by qRT-PCR. A linear regression plot of RSV 815 
nucleoprotein against ISG15 RNA levels in each condition is represented. RSV 816 
nucleoprotein fold induction was obtained by comparison to the donor with the 817 
lowest value of expression, and ISG15 fold induction was calculated relative to 818 
mock-infected cells. (B) Nasopharyngeal wash samples from 19 children infected 819 
with RSV were collected at admission (open circles) and discharge (solid circles) 820 
(38 samples in total) and RNA was extracted and quantified by qRT-PCR. A linear 821 
regression plot of RSV nucleoprotein against ISG15 RNA levels in each sample is 822 
represented. RSV nucleoprotein and ISG15 fold induction were relative to an 823 
external control (a dilution of mRNA  from A549 cells infected with RSV). 824 
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Figure 9. Intracellular ISG15 conjugation-dependent and independent 825 
mechanisms of action. IFN-α/β stimulates the expression of a wide range of 826 
genes termed interferon-stimulated genes (ISGs) involved in the antiviral response. 827 
ISG15 is one of those genes that conjugates to target proteins through a three-step 828 
enzymatic process termed ISGylation, for which the E-1 activating enzyme UbE1L 829 
is required. This process is reversed by the ubiquitin-specific isopeptidase USP18. 830 
In addition, free ISG15 stabilizes USP18 to compete with JAK1 for binding to the 831 
IFNAR2, thereby negatively regulating the IFN-α/β signaling in an isopeptidase-832 
independent manner. The impact of these mechanisms on RSV replication is 833 
discussed in the text. 834 









